Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- ZUSDURI revenue $68.0M, up 35% quarter-over-quarter, with 331 repeat prescribers supporting commercial adoption
- FDA accepted UGN-103 NDA, with PDUFA target date June 14, 2027, creating a potential successor and portfolio expansion
- JELMYTO revenue fell to $21.0M from $25.7M, prompting 2026 guidance reduction to approximately $90M
- Total revenue reached $89.0M, while net loss narrowed to $1.5M from $33.3M year-over-year
- Cash and marketable securities declined to $90.5M, highlighting funding considerations amid $260M to $270M 2026 operating expenses
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.